Zantac recall hits Sanofi Consumer Healthcare

12 February 2020 - Deborah Wilkes

Premium

Sanofi's Consumer Healthcare business reported worldwide sales down by 5.2% at constant exchange rates in the fourth quarter of 2019. The company said the fall was due to the voluntary recall of Zantac (ranitidine), non-core brand divestments, and product suspensions due to changing regulatory requirements, particularly in Europe.

Click tags below for more information on topics:

Sanofi Consumer Healthcare Ranitidine

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: